Castle Biosciences Inc (CSTL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Castle Biosciences Inc (CSTL) has a cash flow conversion efficiency ratio of -0.048x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-22.13 Million) by net assets ($461.42 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Castle Biosciences Inc to measure how much of total assets are equity-financed.
Castle Biosciences Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Castle Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Castle Biosciences Inc earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
Castle Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Castle Biosciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ZENTIVA S.A.
RO:SCD
|
0.012x |
|
Meorient
SHE:300795
|
0.027x |
|
Safe Bulkers Inc
NYSE:SB
|
0.040x |
|
Sparebank 1 Ringerike Hadeland
OL:RING
|
0.191x |
|
Green Dot Corporation
NYSE:GDOT
|
0.101x |
|
Pet Acquisition LLC
NASDAQ:WOOF
|
-0.051x |
|
Inly Media Co Ltd
SHG:603598
|
-1.087x |
|
Ulker Biskuvi Sanayi AS
IS:ULKER
|
0.050x |
Annual Cash Flow Conversion Efficiency for Castle Biosciences Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Castle Biosciences Inc from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Castle Biosciences Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $470.87 Million | $64.35 Million | 0.137x | -3.97% |
| 2024-12-31 | $455.83 Million | $64.87 Million | 0.142x | +1089.66% |
| 2023-12-31 | $391.27 Million | $-5.63 Million | -0.014x | +86.22% |
| 2022-12-31 | $399.15 Million | $-41.66 Million | -0.104x | -126.35% |
| 2021-12-31 | $411.74 Million | $-18.98 Million | -0.046x | -294.27% |
| 2020-12-31 | $415.69 Million | $9.87 Million | 0.024x | -71.21% |
| 2019-12-31 | $85.11 Million | $7.01 Million | 0.082x | -93.25% |
| 2018-12-31 | $-10.07 Million | $-12.29 Million | 1.221x | +42.44% |
| 2017-12-31 | $-14.27 Million | $-12.23 Million | 0.857x | -- |
About Castle Biosciences Inc
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), atopic dermatitis (AD), and uveal melanoma. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the likelihood of a positive sentinel lymph node and the risk of metastasis fo… Read more